<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04265495</url>
  </required_header>
  <id_info>
    <org_study_id>AlBarakaBH-KAMAL</org_study_id>
    <nct_id>NCT04265495</nct_id>
  </id_info>
  <brief_title>Dual Trigger, Urinary HCG or Recombinant HCG, Which is the Best !?</brief_title>
  <official_title>Dual Trigger, Urinary HCG or Recombinant HCG, Which is the Best !? a Prospective Randomized Controlled Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Al Baraka Fertility Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Al Baraka Fertility Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      a comparative study among dual trigger, urinary HCG and recombinant HCG regarding the outcome
      of ICSI- antagonist cycles
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      a comparative study among dual trigger, urinary HCG and recombinant HCG regarding the outcome
      (oocyte quality, fertilization rate, implantation rate, clinical pregnancy rate as well as
      the incidence of OHSS) in ICSI- antagonist cycles
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">August 5, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>clinical pregnancy rate,</measure>
    <time_frame>4 WEEKS</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>implantation rate,</measure>
    <time_frame>2 WEEKS</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of OHSS.</measure>
    <time_frame>1 WEEK</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>IVF</condition>
  <arm_group>
    <arm_group_label>DUAL TRIGGERING</arm_group_label>
    <description>PATIENTS WILL RECEIVE DUAL TRIGGERING</description>
  </arm_group>
  <arm_group>
    <arm_group_label>URINARY HCG</arm_group_label>
    <description>PATIENTS WILL RECEIVE URINARY HCG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RECOMBINANT HCG</arm_group_label>
    <description>PATIENTS WILL RECEIVE RECOMBINANT HCG</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients &lt;40 years of age who underwent IVF/ICSI cycles using a GnRH antagonist protocol,
        then at the time of triggering, we divided the patients to 3 groups by for triggering by a
        dual trigger, urinary HCG and recombinant HCG and then will check the outcome regarding the
        maturity and oocyte quality, implantation rate, clinical pregnancy rate as well as
        incidence of OHSS
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients &lt;40 years of age who underwent IVF/ICSI cycles using a GnRH antagonist
             protocol

        Exclusion Criteria:

          -  age: &gt; 40 years

          -  BMI &gt; 30 ,

          -  long agonist protocol

          -  were chromosomal and genetic disorders, abnormal ultrasonogram of the uterine cavity
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kamal eldin Rageh, M.D.</last_name>
    <phone>0097333153871</phone>
    <email>dr_kamal_rageh@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed Barakat, FRCOG</last_name>
    <phone>0097317727888</phone>
    <email>ahmed.barakat@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Al-BARAKA FERTILITY HOSPITAL</name>
      <address>
        <city>Manama</city>
        <state>Adliya</state>
        <zip>15006</zip>
        <country>Bahrain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AHMED BARAKAT, FRCOG</last_name>
      <phone>0097336660500</phone>
      <email>ahmed_barakat@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Kamal Rageh, M.D</last_name>
      <phone>0097333153871</phone>
      <email>dr_kamal_rageh@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Bahrain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 9, 2020</study_first_submitted>
  <study_first_submitted_qc>February 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Al Baraka Fertility Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Kamal Rageh</investigator_full_name>
    <investigator_title>DOCTOR</investigator_title>
  </responsible_party>
  <keyword>Dual trigger implantation,</keyword>
  <keyword>HCG</keyword>
  <keyword>OHSS</keyword>
  <keyword>ANTAGONIST</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

